Abstract

Activation of thermogenic brown and beige adipocytes is considered as a strategy to improve metabolic control. Here, we identify GPR180 as a receptor regulating brown and beige adipocyte function and whole-body glucose homeostasis, whose expression in humans is associated with improved metabolic control. We demonstrate that GPR180 is not a GPCR but a component of the TGFβ signalling pathway and regulates the activity of the TGFβ receptor complex through SMAD3 phosphorylation. In addition, using genetic and pharmacological tools, we provide evidence that GPR180 is required to manifest Collagen triple helix repeat containing 1 (CTHRC1) action to regulate brown and beige adipocyte activity and glucose homeostasis. In this work, we show that CTHRC1/GPR180 signalling integrates into the TGFβ signalling as an alternative axis to fine-tune and achieve low-grade activation of the pathway to prevent pathophysiological response while contributing to control of glucose and energy metabolism.

Activation of thermogenic adipocytes is a strategy to combat metabolic diseases. Here the authors report that GPR180 is a component of TGFβ signalling that promotes thermogenic adipocyte function and mediates the metabolic effects of the adipocyte-secreted factor CTHRC1, and contributes to the regulation of glucose and energy metabolism.

Details

Title
GPR180 is a component of TGFβ signalling that promotes thermogenic adipocyte function and mediates the metabolic effects of the adipocyte-secreted factor CTHRC1
Author
Balazova Lucia 1 ; Balaz Miroslav 2 ; Horvath, Carla 1 ; Horváth Áron 3 ; Moser, Caroline 1 ; Kovanicova Zuzana 4   VIAFID ORCID Logo  ; Ghosh Adhideb 5   VIAFID ORCID Logo  ; Ghoshdastider Umesh 1 ; Efthymiou Vissarion 1 ; Kiehlmann Elke 1 ; Sun Wenfei 1   VIAFID ORCID Logo  ; Dong, Hua 1   VIAFID ORCID Logo  ; Ding Lianggong 1 ; Ez-Zoubir, Amri 6 ; Nuutila Pirjo 7   VIAFID ORCID Logo  ; Virtanen, Kirsi A 7 ; Niemi Tarja 8 ; Ukropcova, Barbara 9 ; Ukropec Jozef 4 ; Pelczar Pawel 10 ; Lamla Thorsten 11 ; Hamilton, Bradford 12 ; Neubauer Heike 12   VIAFID ORCID Logo  ; Wolfrum, Christian 1   VIAFID ORCID Logo 

 Institute of Food, Nutrition and Health, ETH Zürich, Schwerzenbach, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780) 
 Institute of Food, Nutrition and Health, ETH Zürich, Schwerzenbach, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Institute of Experimental Endocrinology, Biomedical Research Center at the Slovak Academy of Sciences, Bratislava, Slovakia (GRID:grid.424960.d); Comenius University in Bratislava, Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Bratislava, Slovakia (GRID:grid.7634.6) (ISNI:0000000109409708) 
 University Hospital Balgrist, University of Zurich, Biomechanics Laboratory, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Institute of Biomechanics, ETH Zurich, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780) 
 Institute of Experimental Endocrinology, Biomedical Research Center at the Slovak Academy of Sciences, Bratislava, Slovakia (GRID:grid.424960.d) 
 Institute of Food, Nutrition and Health, ETH Zürich, Schwerzenbach, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Functional Genomics Centre Zurich, ETH Zurich/ University of Zurich, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650) 
 Université Côte d’Azur, French National Centre for Scientific Research, Inserm, iBV, Nice, France (GRID:grid.461605.0) 
 University of Turku, Turku PET Centre, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371) 
 Turku University Hospital, Department of Surgery, Turku, Finland (GRID:grid.410552.7) (ISNI:0000 0004 0628 215X) 
 Institute of Experimental Endocrinology, Biomedical Research Center at the Slovak Academy of Sciences, Bratislava, Slovakia (GRID:grid.424960.d); Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia (GRID:grid.7634.6) (ISNI:0000000109409708) 
10  University of Basel, Center for Transgenic Models, Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642) 
11  Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500) 
12  Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riss, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2607919534
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.